1513 related articles for article (PubMed ID: 15982565)
41. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.
Donckier V; Troisi R; Toungouz M; Colle I; Van Vlierberghe H; Jacquy C; Martiat P; Stordeur P; Zhou L; Boon N; Lambermont M; Schandené L; Van Laethem JL; Noens L; Gelin M; de Hemptinne B; Goldman M
Transpl Immunol; 2004; 13(2):139-46. PubMed ID: 15380544
[TBL] [Abstract][Full Text] [Related]
42. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
[TBL] [Abstract][Full Text] [Related]
43. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
44. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
[TBL] [Abstract][Full Text] [Related]
45. Allogenic stem cell transplantation following non-myeloablative conditioning regimens as adoptive immunotherapy in patients with hematological malignancies.
Busca A; Bruno B; Boccadoro M; Locatelli F; Falda M
Med Sci Monit; 2002 Oct; 8(10):RA221-32. PubMed ID: 12388932
[TBL] [Abstract][Full Text] [Related]
46. Nonmyeloablative stem cell transplantation for the treatment of cancer and life-threatening nonmalignant disorders: past accomplishments and future goals.
Slavin S; Or R; Aker M; Shapira MY; Panigrahi S; Symeonidis A; Cividalli G; Nagler A
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S79-84. PubMed ID: 11587373
[TBL] [Abstract][Full Text] [Related]
47. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
48. Allogeneic transplantation using non-myeloablative transplant regimens.
Battiwalla M; Barrett J
Best Pract Res Clin Haematol; 2001 Dec; 14(4):701-22. PubMed ID: 11924917
[TBL] [Abstract][Full Text] [Related]
49. Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor.
Magro E; Regidor C; Cabrera R; Sanjuán I; Forès R; Garcia-Marco JA; Ruiz E; Gil S; Bautista G; Millán I; Madrigal A; Fernandez MN
Haematologica; 2006 May; 91(5):640-8. PubMed ID: 16670070
[TBL] [Abstract][Full Text] [Related]
50. A non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients.
Tsirigotis P; Bitan RO; Resnick IB; Samuel S; Ackerstein A; Eladì S; Gesundheit B; Zilberman I; Miron S; Leubovic A; Slavin S; Shapira MY
Haematologica; 2006 Jun; 91(6):852-5. PubMed ID: 16769592
[TBL] [Abstract][Full Text] [Related]
51. Current concepts in allogeneic hematopoietic stem cell transplantation.
Tabbara IA; Kairouz S; Nahleh Z; Mihalcea AM
Anticancer Res; 2003; 23(6D):5055-67. PubMed ID: 14981967
[TBL] [Abstract][Full Text] [Related]
52. Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used.
Bartsch K; Al-Ali H; Reinhardt A; Franke C; Hudecek M; Kamprad M; Tschiedel S; Cross M; Niederwieser D; Gentilini C
Transplantation; 2009 Jan; 87(2):217-21. PubMed ID: 19155975
[TBL] [Abstract][Full Text] [Related]
53. Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent.
Bitan M; Or R; Shapira MY; Resnick IB; Ackerstein A; Samuel S; Elad S; Slavin S
Haematologica; 2005 Aug; 90(8):1089-95. PubMed ID: 16079108
[TBL] [Abstract][Full Text] [Related]
54. Hematopoietic stem cell therapy for malignant diseases.
Shapira MY; Hai AA; Tsirigotis P; Resnick IB; Or R; Slavin S
Ann Med; 2007; 39(6):465-73. PubMed ID: 17852026
[TBL] [Abstract][Full Text] [Related]
55. High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation.
Passweg JR; Meyer-Monard S; Gregor M; Favre G; Heim D; Ebnoether M; Tichelli A; Gratwohl A
Bone Marrow Transplant; 2002 Sep; 30(5):267-71. PubMed ID: 12209347
[TBL] [Abstract][Full Text] [Related]
56. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies.
Chen X; Hale GA; Barfield R; Benaim E; Leung WH; Knowles J; Horwitz EM; Woodard P; Kasow K; Yusuf U; Behm FG; Hayden RT; Shurtleff SA; Turner V; Srivastava DK; Handgretinger R
Br J Haematol; 2006 Nov; 135(4):524-32. PubMed ID: 17010105
[TBL] [Abstract][Full Text] [Related]
57. Immunotherapy by allogeneic stem cell transplantation.
Ringdén O
Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
[TBL] [Abstract][Full Text] [Related]
58. Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation.
Kornblit B; Masmas T; Petersen SL; Madsen HO; Heilmann C; Schejbel L; Sengeløv H; Müller K; Garred P; Vindeløv L
Biol Blood Marrow Transplant; 2010 Feb; 16(2):239-52. PubMed ID: 19819342
[TBL] [Abstract][Full Text] [Related]
59. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
Du B; Li DP; Xu KL; Pan XY
Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
[TBL] [Abstract][Full Text] [Related]
60. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches.
Friedman TM; Varadi G; Hopely DD; Filicko J; Wagner J; Ferber A; Martinez J; Brunner J; Grosso D; McGuire L; Korngold R; Flomenberg N
Biol Blood Marrow Transplant; 2001; 7(12):656-64. PubMed ID: 11787528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]